ReviewPhilosophical transactions. Series A, Mathematical, physical, and engineering sciences2015
Third row transition metals for the treatment of cancer.
Review in Philosophical transactions. Series A, Mathematical, physical, and engineering sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 128 citations in OpenAlex.
- Pro-Apoptotic Organometallic Sn(IV) Bis-Organosilane Benzoate Complexes with Sustained Reduction in Cell Viability Under Resistance-like Conditions in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Machine learning-based fabrication of phytogenic NiO nanoparticles for anticancer activity in HepG2 Cell Culture.Journal of materials science. Materials in medicine · 2025Article
- CO Complexation by Ru(II) and Os(II) Porphyrin Complexes Sheds Light on the Relative Importance of Thermodynamic Stability and Kinetic Lability for CO Poisoning Antidotes.Organometallics · 2025Article
- Review
- Article
- Recent Advances in Anticancer Research of Osmium and Rhodium Complexes.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Review
- Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer.Cancer medicine · 2024Article
- Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.Journal of medicinal chemistry · 2024Article
- Zeolitic Imidazole Framework/Silica Nanocomposite for Targeted Cancer Therapeutics: Comparative Study of Chemo-Drug Cisplatin (CPt) and Green Platinum (GPt) Efficacy.International journal of molecular sciences · 2024Article
- The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs.International journal of molecular sciences · 2023Review
- Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study.Pharmaceutics · 2023Article
- Metallo-Drugs in Cancer Therapy: Past, Present and Future.Molecules (Basel, Switzerland) · 2022Review
- Nanocarriers containing platinum compounds for combination chemotherapy.Frontiers in pharmacology · 2022Review
- Platinum-based drugs for cancer therapy and anti-tumor strategies.Theranostics · 2022Review
- Cancer therapeutic strategies based on metal ions.Chemical science · 2021Review
- NMR studies of group 8 metallodrugs:Dalton transactions (Cambridge, England : 2003) · 2021Article
- Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents.ACS omega · 2021Article
- Article
- Arene Ruthenium(II) Complexes Bearing the κ-Molecules (Basel, Switzerland) · 2021Article
- Dose- and time-dependent tolerability and efficacy of organo-osmium complex FY26 and its tissue pharmacokinetics in hepatocarcinoma-bearing mice.Metallomics : integrated biometal science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Platinum compounds are a mainstay of cancer chemotherapy, with over 50% of patients receiving platinum. But there is a great need for improvement. Major features of the cisplatin mechanism of action involve cancer cell entry, formation mainly of intrastrand cross-links that bend and unwind nuclear DNA, transcription inhibition and induction of cell-death programmes while evading repair. Recently, we discovered that platinum cross-link formation is not essential for activity. Monofunctional Pt compounds such as phenanthriplatin, which make only a single bond to DNA nucleobases, can be far more active and effective against a range of tumour types. Without a cross-link-induced bend, monofunctional complexes can be accommodated in the major groove of DNA. Their biological mechanism of action is similar to that of cisplatin. These discoveries opened the door to a large family of heavy metal-based drug candidates, including those of Os and Re, as will be described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.